The calling card of Alzheimer’s disease is a buildup of misfolded amyloid protein in the brain, but many medicines struggle to penetrate the barrier protecting the mind from outside interference. A ...

Leerink Partners analysts slashed their sales forecast for enGene Therapeutics’ bladder cancer candidate after phase 2 data ...

Since then, Odyssey has had no problems bringing in the megarounds. As well as the $218 million that the company launched ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Banyan BioInnovations is debuting with more than $100 million aimed at developing independent companies for promising clinical-stage treatments, plus a partnership with global contract research ...

BeOne Medicines has shaken up its early pipeline, dropping five phase 1 cancer programs and stopping a phase 2 arthritis ...

Ascendis Pharma has ended internal development of its IL-2 candidate, pivoting away from oncology and calling time on an ...

Entrada identified lower-than-expected plasma exposure in juvenile DMD patients as the cause of the lackluster data. Exposure ...

Though a measles vaccine has existed for more than 60 years, much still remains unknown about how exactly the shot generates protection against the virus. Now, scientists have turned to the immune ...

For people living with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), the only treatment option is a regimen that can include up to 40 pills a day. With a $250 million investment ...

Roche is set to pay out $750 million upfront to acquire digital pathology specialist Path AI in a move by the pharma giant to accelerate the use of artificial intelligence in diagnostic algorithms.

From shrinking drug development timelines to scouting potential acquisitions, the recent run of first-quarter earnings results marked a shift for Big Pharma from AI hype to explaining how the ...